Serum Interleukin 17 as a Marker for Alopecia Areata Severity: A Case-Control Study
April 2023
in “
The Egyptian Journal of Hospital Medicine
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary This case control study investigated serum IL-17A levels in alopecia areata patients compared to healthy controls to explore its potential role in the disease's pathogenesis.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study investigated the role of serum interleukin-17 (IL-17) in alopecia areata (AA) by comparing 26 AA patients with 26 healthy controls. Results showed that IL-17 levels were significantly higher in AA patients, ranging from 133 to 326 pg/ml, compared to 14 to 226 pg/ml in controls. Despite the elevated IL-17 levels, no significant differences were found concerning clinical types, age, gender, disease duration, or severity. The findings suggest that IL-17 contributes to hair follicle destruction in AA, indicating that IL-17 inhibitors could be beneficial, particularly in resistant AA cases.
